Researchers at the Cleveland Clinic are recruiting 15 adult patients for an open-label trial to assess the safety and efficacy of H.P. Acthar gel for treating the skin symptoms in patients with refractory dermatomyositis, juvenile dermatomyositis, and amyopathic dermatomyositis.
H.P. Acthar gel is an adrenocorticotropic hormone preparation that received FDA approval for treatment of a variety of diseases, including dermatomyositis, in 1952. Despite this, there is little clinical data about the efficacy of H.P. Acthar gel for treating dermatomyositis.
Participants will receive two subcutaneous (under the skin) injections per week for 24 weeks.
For more information about this trial, please contact Lisa Rittwage at 216-444-4659.
Find more information about this trial here.
More information on other clinical trials for myositis can be found here.